Scil Proteins acquires Tat Phage display from ipal GmbH and Charité
Until now, Scil Proteins’ screening process was based on the Ribosome Display technology, accessed in 2006 in a cross-licensing deal with CAT/MedImmune. The combination of Tat Phage display with Ribosome Display enhances both the speed and reliability of the screening process.
“We are delighted to have secured exclusive rights to the use of these unique state of the art screening and selection techniques,” commented Dr. Ulrike Fiedler, CEO of Scil Proteins. “This further strengthens our competitive position for the Affilin® therapeutics platform.”
Scil Proteins will use this combined screening capability to identify Affilin® lead therapeutic candidates in the core indications of cancer and inflammation/infectious diseases.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.